eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
2/2003
vol. 7
 
Share:
Share:
abstract:

Ocular complications of tamoxifen: case report and literature review

Radosław Różycki
,
Anna Hyży-Topolewska
,
Janusz Wojtacki
,
Krzysztof Leśniewski-Kmak

Współcz Onkol (2003) vol. 7; 2 (116-121)
Online publish date: 2003/04/10
View full text Get citation
 
Tamoxifen is a synthetic antiestogen used as endocrine therapy in women with estrogen and/or progesterone-receptor positive breast cancers, despite the stage of the disease and age as well, both as a treatment for advanced cancer and in adjuvant setting; its potential use as a chemopreventive agent is currently under investigation. As more than thirty-years of experience show, tamoxifen is a well tolerated and safe drug and its side effects are usually moderate and transient (hot flashes, vaginal discharge, headache, and, rarely, nausea and skin rashes). Ocular toxicity is rather rare tamoxifen-related complication: the incidence reported in retrospective studies ranges from 0 to 23.5%, depending on the daily and cumulative tamoxifen dose and the methodology of the study. Tamoxifen may destroy almost each part of the visual system, but retinopathy as well keratopathy (usually asymptomatic) are relatively characteristic, whereas optic neuritis is relatively rare. The study reports a case of 48-year-old breast cancer women (pT2pN0M0, grade II according to Bloom-Richarson criteria, positive staining for estrogen and progesterone receptors), who experienced reversible decreased bilateral visual acuity with retinopathy after six months of adjuvant therapy (daily dose: 20 mg/d., cumulative dose: 3.7 g). Other reasons of visual disturbances were excluded due to the precise medical history and differential diagnostic procedures. Following 4 weeks of tamoxifen discontinuation all visual symptoms regressed as well as the changes observed at the fundus of the eye. The current literature on the topic is reviewed and discussed, particularly in relation to epidemiology, risk factors, clinical course, differential diagnosis and screening guidelines of the complication.
keywords:

tamoxifen, breast cancer, ocular toxicity, retinopathy, keratopathy

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.